|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's range||188.37 - 196.01|
|52-week range||162.29 - 327.32|
|Beta (5Y monthly)||0.77|
|PE ratio (TTM)||89.70|
|Earnings date||22 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||312.56|
Repligen (NASDAQ: RGEN) and ResMed (NYSE: RMD) are two stocks which could fit that bill with their proven track records and growing opportunities. Repligen offers a unique way to invest in the healthcare space. Operating in both the downstream and upstream processes of drug development, Repligen sells products in the areas of filtration, chromatography, process analytics, and proteins.
The FDA agrees to the initiation of rolling submission of Gamida's (GMDA) BLA for its lead blood cancer candidate, omidubicel. The stock rises more than 22% on in response.
If you've got the time and intestinal fortitude to deal with a stock's big ups and downs, a big potential payoff awaits. If you think Advanced Micro Devices (NASDAQ: AMD) is always behind Nvidia in the graphics card market while at the same time perpetually playing second fiddle to Intel within the computer processor arena, you're right. Namely, Advanced Micro Devices' hardware is a favorite among hardcore video gamers because it's affordable without sacrificing performance.